Sutro Biopharma Announces Participation at the 16th World ADC London Summit

Rhea-AI Summary

Sutro Biopharma (NASDAQ: STRO) will participate at the 16th World ADC London Summit in London, UK, February 23-26, 2026. Senior scientist Hans-Peter Gerber, Ph.D. will join panel discussions and present on dual-payload ADC efficacy and safety.

According to the company, plenary content will be posted in Sutro's Scientific Publications section after the event.

Key Figures

Conference edition: 16th World ADC London Summit Conference dates: February 23–26, 2026 Panel time 1: February 23, 2026, 3:00PM GMT +2 more

5 metrics

Conference edition 16th World ADC London Summit Event Sutro is participating in

Conference dates February 23–26, 2026 World ADC London Summit schedule

Panel time 1 February 23, 2026, 3:00PM GMT ADC licensing, partnering & investment session

Panel time 2 February 24, 2026, 7:45AM GMT Cutting-edge ADC innovation & performance discussion

Presentation time February 25, 2026, 9:00AM GMT Dual payload ADCs efficacy & safety presentation

Market Reality Check

Price: $18.42 Vol: Volume 121,783 vs 20-day ...

normal vol

$18.42 Last Close

Volume Volume 121,783 vs 20-day average 129,335 (relative volume 0.94) shows no unusual trading. normal

Technical Shares at $18.42, trading above the 200-day MA of $9.86 and 7.44% below the 52-week high of $19.90.

Peers on Argus

STRO fell 5.83% while peers were mixed: ATRA -1.88%, IGMS -2.31%, OKYO -6.59%, X...

1 Up

STRO fell 5.83% while peers were mixed: ATRA -1.88%, IGMS -2.31%, OKYO -6.59%, XBIT -2.94%, ENTX +6.52%. This points to stock-specific dynamics rather than a broad sector move.

Common Catalyst One peer, ATRA, reported a business update, but broader ADC/biotech peers lack a shared news catalyst today.

Historical Context

5 past events · Latest: Feb 10 (Negative)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 10	Equity offering	Negative	+11.9%	Underwritten offering of 7,868,383 shares at $13.98 raising ~$110M.
Jan 07	Conference appearance	Neutral	+2.0%	J.P. Morgan Healthcare Conference presentation by the CEO announced.
Dec 17	Listing compliance	Positive	-6.9%	Regained Nasdaq minimum bid price compliance after reverse stock split.
Dec 16	Equity incentives	Neutral	-1.2%	Inducement grants of stock options and RSUs to new employees.
Dec 03	Clinical trial start	Positive	+19.2%	First cohort dosed in Phase 1 trial of STRO‑004 in solid tumors.

Pattern Detected

Recent history shows strong positive moves on financings and clinical milestones, with occasional selloffs even on favorable listing/compliance updates.

Recent Company History

Over the last few months, Sutro Biopharma has combined financing, clinical, and listing milestones. On Dec 3, 2025, it dosed the first cohort in a Phase 1 trial of STRO‑004, which saw a 19.21% gain. It later regained Nasdaq minimum bid compliance on Dec 17, 2025, despite a -6.93% reaction. An underwritten offering priced on Feb 10, 2026 raised about $110.0M and coincided with an 11.87% rise. Conference participation and routine equity grants have produced smaller, mixed moves. Today’s conference-focused announcement fits this pattern of frequent corporate visibility events around a strengthened balance sheet and advancing ADC programs.

Market Pulse Summary

This announcement highlights Sutro Biopharma’s scientific and business visibility at the 16th World ...

Analysis

This announcement highlights Sutro Biopharma’s scientific and business visibility at the 16th World ADC London Summit, including panels on licensing, partnering, investment, and dual‑payload ADC innovation. In recent months, the company has strengthened its capital position with an approximately $110.0M offering and advanced its STRO‑004 Phase 1 program, which previously triggered a 19.21% move. Investors evaluating this news may watch for subsequent scientific materials posted on the company’s website and for future clinical or financial updates that add to this conference exposure.

Key Terms

antibody drug conjugates, adcs, dual payload adcs

3 terms

antibody drug conjugates medical

"a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs)"

Antibody drug conjugates are targeted medicines that combine an antibody, which seeks out specific markers on diseased cells, with a powerful drug that is released only when the antibody binds its target. Think of it as a guided missile that delivers a toxic payload directly to its target, reducing damage to healthy cells; investors watch them because successful ADCs can offer high-value, niche treatments and drive strong revenue and patent-based protection for developers.

adcs medical

"pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced"

Antibody-drug conjugates (ADCs) are targeted cancer medicines that combine an antibody, which seeks out specific markers on tumor cells, with a powerful drug payload that is released once the antibody binds its target. Think of them as a guided missile that delivers a toxic package directly to diseased cells to limit harm to healthy tissue. Investors watch ADC news closely because clinical trial results, manufacturing complexity and regulatory decisions can sharply change a biotech company’s value.

dual payload adcs medical

"Spotlighting Efficacy & Safety Profiles of Dual Payload ADCs Featuring Novel Linker Payloads"

Dual payload ADCs are targeted cancer therapies that use an antibody as a guided delivery vehicle to carry two different toxic drugs directly into tumor cells. Think of it as a delivery van that drops off two types of tools at the same address to tackle different problems at once, which can improve effectiveness and reduce the chance cancer will escape treatment. Investors watch them because they can offer stronger clinical benefits but also bring higher development cost, regulatory scrutiny, and commercial risk.

AI-generated analysis. Not financial advice.

SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced its participation at the 16th World ADC London Summit, taking place in London, UK, February 23-26, 2026.

Plenary/Panel Discussion Details:

• Panel Discussion: ADC Licensing, Partnering & Investment Session
  • Sutro Participant: Hans-Peter Gerber, Ph.D.
  • Date/Time: February 23, 2026, 3:00PM GMT
    
    
• Panel Discussion: Evaluating the Cutting-Edge Innovation & Performance Driving ADC Differentiation & Progression Earlier Line Patient Therapies
  
  • Sutro Participant: Hans-Peter Gerber, Ph.D.
  • Date/Time: February 24, 2026, 7:45AM GMT
    
    
• Spotlighting Efficacy & Safety Profiles of Dual Payload ADCs Featuring Novel Linker Payloads to Overcome Resistance Mechanisms
  • Presenter: Hans-Peter Gerber, Ph.D.
  • Date/Time: February 25, 2026, 9:00AM GMT

Following the event, the content from the plenary session will be made available in the Scientific Publications section of Sutro Biopharma’s website at www.sutrobio.com.

About Sutro Biopharma
Sutro Biopharma, Inc. is advancing a next-generation antibody-drug conjugate (ADC) platform designed to deliver single- and dual-payload ADCs that enable meaningful breakthroughs for patients with cancer. By fully optimizing the antibody, linker, and payload, Sutro’s cell-free platform produces ADCs that are engineered to improve drug exposure, reduce side effects, and expand the range of treatable tumor types. With unique capabilities in dual-payload ADCs, Sutro aims to overcome treatment resistance and redefine what’s possible in cancer therapy. The Company’s pipeline of single- and dual-payload ADCs targets large oncology markets with limited treatment options and significant need for improved therapies.

For more information, follow Sutro on social media @Sutrobio or visit www.sutrobio.com.

Investor Contact
Emily White
Sutro Biopharma
(650) 823-7681
ewhite@sutrobio.com

Media Contact
Amy Bonanno
Lyra Strategic Advisory
abonanno@lyraadvisory.com

FAQ

When will Sutro Biopharma (STRO) present at the 16th World ADC London Summit in February 2026?

Sutro will participate February 23-26, 2026 at the World ADC London Summit. According to the company, Hans-Peter Gerber, Ph.D. will take part in panel sessions on Feb 23 and Feb 24 and present on Feb 25, with times listed in the event schedule.

Which Sutro representative speaks at the World ADC London Summit and what topics will STRO cover?

Hans-Peter Gerber, Ph.D. represents Sutro and will discuss ADC licensing, partnering, and innovation. According to the company, sessions cover evaluating ADC differentiation, dual-payload efficacy, safety profiles, and novel linker payloads to address resistance mechanisms.

What time are Sutro's panel discussions and presentation at the February 2026 ADC conference?

Sutro's sessions are Feb 23 at 3:00 PM GMT, Feb 24 at 7:45 AM GMT, and Feb 25 at 9:00 AM GMT. According to the company, those are the scheduled times for the panel discussions and the dual-payload ADC presentation.

Will Sutro (STRO) publish the World ADC London Summit presentation materials online after the event?

Yes, Sutro plans to post plenary session content in its Scientific Publications section after the summit. According to the company, attendees and investors can access the materials on Sutro's website following the event.

How can investors access Sutro Biopharma (STRO) conference content from the World ADC London Summit?

Investors can view post-event materials on Sutro's website under Scientific Publications. According to the company, plenary content from the summit will be made available there following the conclusion of the conference.